中文产业新闻精选评分86Chinese source
武田Orzeyful获FDA批准，为首款靶向食欲素信号缺失的1型发作性睡病疗法
突破性疗法今日获FDA批准，曾入选“明星分子”榜单
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
突破性疗法今日获FDA批准，曾入选“明星分子”榜单
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.